Efficacy of Combination Therapy with Carolizumab and Sox Regimen in the Treatment of Advanced Gastric Cancer
Objective To explore the clinical efficacy of carolizumab combined with SOX regimen(oxaliplatin+tigio)in the treatment of advanced gastric cancer,and to provide experience for improving the treatment effect of advanced gastric cancer in clinical practice.Methods A total of 100 patients with advanced gastric cancer admitted to the Second Affiliated Hospital of Henan University of Science and Technology from August 2020 to August 2022 were selected and divided into observation group and control group by random number table method with 50 cases in each group.The control group was treated with SOX regimen,and the observation group was treated with carolizumab for 6 cycles.The clinical efficacy,immune function indexes(CD3+,CD4+,CD8+,CD4+/CD8+)and tumor markers[carcinoembryonic antigen(CEA),serum carbohydrate antigen 199(CA199),serum carbohydrate antigen 724(CA724)]were evaluated and compared between the two groups,and the occurrence of toxic and side effects during treatment was observed.Results Among the 100 patients,both the observation group and the control group had 3 cases removed due to death or abandonment of treatment.A total of 94 cases completed 6 cycles of treatment,and the clinical efficacy of the observation group was higher than control group(P＜0.05).Both groups of CD3+,CD4+,and CD4+/CD8+showed a decrease after treatment,and observation group was higher than control group(P＜0.05).The levels of CEA,CA199,and CA724 in two groups decreased,and compared with control group,the observation group was lower(P＜0.05).There was no significant difference in the incidence of toxic side effects between the two groups(P＞0.05).Conclusion The clinical effect of using carolizumab combined with SOX regimen in the treatment of advanced gastric cancer is significant,which can avoid patients'immune function decline and lower tumor marker levels,and has good safety.
advanced gastric cancercarolizumaboxaliplatintigioclinical efficacyimmune function
万方数据
维普
